Candel Therapeutics CADL 深 滬
已收盤 08-07 16:00:00 美东时间
10.59
+0.010
+0.09%
華盛通- 最 高10.74
- 今 開10.69
- 成交量 80.08万股
- 最 低 10.52
- 昨 收 10.58
- 總市值 7.76亿
- 52周最高 11.3599
- 市盈率 靜 --
- 換手率 1.09%
- 52周最低 4.35
- 委 比 -76.83%
- 總股本 7327.02万
- 歷史最高 14.78
- 量 比 0.78
- 振 幅 2.08%
- 歷史最低 0.66
- 每 手 1
- 風險率 1.72%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Candel Therapeutics granted stock options to three new employees, totaling 30,800 shares with an exercise price of $10.01 per share, under its 2025 Inducement Plan. The options vest 25% after one year and the remaining 75% in 36 monthly installments, contingent on continued employment. The company focuses on developing multimodal immunotherapies for cancer, with key products CAN-2409 and CAN-3110 in clinical trials, receiving FDA designations inc...
08-03 20:05
美股大行评级 | 花旗上调苹果、西部数据、希捷科技、超微电脑等目标价；高盛上调蔚来"买入"评级，目标价7美元
今日重点评级关注：HC Wainwright & Co.：维持艾吉纳斯"买入"评级，目标价从23美元升至30美元；富国银行：上调Q32 Bio评级至"超配"，目标价66美元
07-14 11:36
Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22
Stifel analyst Stephen Willey initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $22.
07-13 17:53
Candel Therapeutics Announces Lancet Oncology Publication Of Phase 3 Data Showing 30% DFS Improvement For Aglatimagene Besadenovec In Localized Prostate Cancer
Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative intent
06-02 20:19
Candel Therapeutics Presents New Results From Extended Follow-Up Of Randomized, Double-Blind, Placebo-Controlled Pivotal Phase 3 Trial Of Aglatimagene Besadenovec In Prostate Cancer At AUA 2026 Annual Meeting
Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prostate cancer–specific
05-16 04:07
Candel Therapeutics Q1 EPS $(0.14) Beats $(0.34) Estimate
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.34) by 58.82 percent. This is a 207.69 percent decrease over earnings of $0.13 per share
05-14 20:12
Candel Therapeutics To Hold Conference Call On May 15 To Discuss Extended Follow-Up Data From Its Phase 3 Clinical Study Of Aglatimagene Besadenovec In Participants With Intermediate- To High-Risk Localized Prostate Cancer
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced
05-04 20:17
Cantor Fitzgerald Initiates Coverage On Candel Therapeutics with Overweight Rating
Cantor Fitzgerald initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Overweight rating.
04-20 23:08
10 Health Care Stocks Moving In Friday's Intraday Session
Gainers Psyence Biomedical (NASDAQ:PBM) shares increased by 40.5% to $8.25 dur...
04-18 01:05
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
